BMC Cancer (Dec 2022)

Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

  • Abolghasem Allahyari,
  • Ali Ehsanpour,
  • Behrouz Najafi,
  • Nafseh Ansarinejad,
  • Valiollah Mehrzad,
  • Behjat Kalantari,
  • Jahangir Raafat,
  • Mojtaba Ghadiany,
  • Farhad Shahi,
  • Behrooz Gharib,
  • Vahid Moazed,
  • Adnan Khosravi,
  • Mir Hossein Mirpour,
  • Sina Salari,
  • Seyedmohammadreza Mortazavizadeh,
  • Amirabbas Nekoyi,
  • Mohsen Khani,
  • Alireza Sadeghi,
  • Sirus Gharib,
  • Alireza Bary,
  • Mehrzad Mirzania,
  • Shirin Haghighat,
  • Seyed Mohsen Razavi,
  • Seyed Amir Hossein Emami,
  • Mehran Hosseinzadeh,
  • Mahdi Mirbolouk,
  • Sanambar Sadighi,
  • Abdolali Shahrasbi,
  • Ali Esfahani,
  • Masoumeh Gity,
  • Nassim Anjidani,
  • Hamidreza Kaf,
  • Safa Najaf

DOI
https://doi.org/10.1186/s12885-022-10455-0
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 2

Abstract

Read online

No abstracts available.